Buffett's Berkshire reveals new bets on Royalty Pharma, exits Merck in Q3

Warren Buffett's Berkshire Hathaway built new stakes in $Floor & Decor(FND.US)$ and $Royalty Pharma(RPRX.US)$ in the third quarter, a regulatory filing revealed on Monday. The famed investor's company also took a knife to several of its pharmaceutical and financial holdings in the period.

On the other hand, Berkshire boosted its $Chevron(CVX.US)$ stake by 24%, after halving its position in the energy group in the first quarter of this year, and trimming it even more in the second quarter.

Buffett's company exited $Merck & Co(MRK.US)$, $Organon & Co(OGN.US)$, and $Liberty Global-A(LBTYA.US)$. It also cut its $AbbVie(ABBV.US)$and $Bristol-Myers Squibb(BMY.US)$ positions by 30% and 16% respectively last quarter, despite only adding those names to its portfolio in the third quarter of last year. Moreover, it trimmed its $Visa(V.US)$, $MasterCard(MA.US)$, $Charter Communications(CHTR.US)$, and $Marsh & McLennan(MMC.US)$.